Current Smoking, Vaping Linked to Symptom Burden in Cancer
22 May 2023
Clinical Result
Sarah N. Price, Ph.D., from the Wake Forest University School of Medicine in Winston-Salem, North Carolina, and colleagues examined the association between tobacco use and symptom burden among 1,409 adult cancer survivors. The association between cigarette smoking and vaping on cancer-related symptom burden (fatigue, pain, emotional problems) and quality of life (QoL) was assessed.
The researchers found that the weighted rate of cigarette smoking was 14.21 percent and the weighted rate of vaping was 2.88 percent. Current smoking was associated with greater fatigue, pain, emotional problems, and worse QoL, while current vaping was associated with greater fatigue, pain, and emotional problems, but not worse QoL. There was no association observed for higher cancer symptom burden with reduced interest in quitting, likelihood of quitting, or odds of past-year quit attempts.
"Our finding that greater symptom burden was not associated with reduced interest in quitting smoking directly contradicts common assumptions that patients with cancer are resistant to tobacco cessation treatment because of their symptom burden. If smoking cessation is viewed as part of cancer symptom management, it may be more acceptable to both patients and the clinicians who treat them," Price said in a statement. "Future research should also explore whether better management of cancer symptoms like pain, fatigue, or emotional problems helps survivors quit smoking."
One author disclosed ties to Imbrium Therapeutics, another to Castle Biosciences; one author has testified on behalf of plaintiffs who have filed litigation against the tobacco industry.
Abstract/Full Text
Posted May 2023
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Targets
-Drugs
-Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.